RSV Vaccine Candidate Stimulates Immune Responses from the Humoral, Cellular, Mucosal Pillars of the Immune System

Blue Lake Biotechnology, Inc. and its affiliate CyanVac LLC today announced the presentation of positive interim pediatric clinical data on BLB201, Blue Lake’s vaccine candidate against respiratory syncytial virus (RSV).

Hong Jin, Ph.D., Chief Scientific Officer of Blue Lake and CyanVac, presented a talk that included results from an interim analysis of RSV-seropositive children participating in the company’s ongoing Phase 1/2a pediatric study.

The data demonstrated the safety and immunogenicity of BLB201 in this population, including RSV F-specific systemic and mucosal antibody responses and cell-mediated immune responses in CD4+ and CD8+ T cells.

“Our vaccine approach is designed to stimulate potent immune responses from the humoral, cellular, and mucosal pillars of the immune system,” said Biao He, Ph.D., CEO of Blue Lake and CyanVac, in a press release on October 21, 2024.

“Many currently available vaccine technologies such as mRNA and protein-based vaccines are ineffective in inducing mucosal immunity because they are given intramuscularly."

"By robustly stimulating all three pillars of immunity, our intranasal vaccine may prevent disease transmission and generate longer-lasting immunity than other types of vaccines.”